ArticleCommunications biology2021
GardeninA confers neuroprotection against environmental toxin in a Drosophila model of Parkinson's disease.
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Plant-derived soft electrophiles upregulate pro-resolving oxylipins in a paraquat-inducedbioRxiv : the preprint server for biology · 2026Article
- In Vitro Antioxidant Activity and In Vivo Neuroprotective Effect ofAntioxidants (Basel, Switzerland) · 2025Article
- Modulation of TNFα-driven neuroinflammation by Gardenin A: insights fromFrontiers in pharmacology · 2025Article
- Review
- Gardenin A treatment attenuates inflammatory markers, synuclein pathology and deficits in tyrosine hydroxylase expression and improves cognitive and motor function in A53T-α-syn mice.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024Article
- A Simple Immunofluorescence Method to Characterize Neurodegeneration and Tyrosine Hydroxylase Reduction in Whole Brain of aBio-protocol · 2024Article
- Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics.Scientific reports · 2023Article
- Review
- Neuroprotection of isookanin against MPTP-induced cell death of SH-SY5Y cells via BCL2/BAX and PI3K/AKT pathways.Psychopharmacology · 2023Article
- Predicting structural features of selected flavonoids responsible for neuroprotection in a Drosophila model of Parkinson's disease.Neurotoxicology · 2023Article
- Use of invertebrates to model chemically induced parkinsonism-symptoms.Biochemical Society transactions · 2023Review
- Fluorescence microscopy-based sensitive method to quantify dopaminergic neurodegeneration in aFrontiers in neuroscience · 2023Article
- Effect of Solanum vegetables on memory index, redox status, and expressions of critical neural genes in Drosophila melanogaster model of memory impairment.Metabolic brain disease · 2022Article
- Drug discovery from natural products - Old problems and novel solutions for the treatment of neurodegenerative diseases.Journal of pharmaceutical and biomedical analysis · 2022Review
- Calycosin Alleviates Paraquat-Induced Neurodegeneration by Improving Mitochondrial Functions and Regulating Autophagy in aAntioxidants (Basel, Switzerland) · 2022Article
- Adult health and transition stage-specific rotenone-mediatedFrontiers in molecular neuroscience · 2022Article
- The Combination of Tradition and Future: Data-Driven Natural-Product-Based Treatments for Parkinson's Disease.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Nano-hesperetin ameliorates 6-hydroxydopamine-induced behavioral deficits and oxidative damage by up-regulating gene expression of antioxidant enzymes.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is an age-associated neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons from the midbrain. Epidemiological studies have implicated exposures to environmental toxins like the herbicide paraquat as major contributors to Parkinson's disease etiology in both mammalian and invertebrate models. We have employed a paraquat-induced Parkinson's disease model in Drosophila as an inexpensive in vivo platform to screen therapeutics from natural products. We have identified the polymethoxyflavonoid, GardeninA, with neuroprotective potential against paraquat-induced parkinsonian symptoms involving reduced survival, mobility defects, and loss of dopaminergic neurons. GardeninA-mediated neuroprotection is not solely dependent on its antioxidant activities but also involves modulation of the neuroinflammatory and cellular death responses. Furthermore, we have successfully shown GardeninA bioavailability in the fly heads after oral administration using ultra-performance liquid chromatography and mass spectrometry. Our findings reveal a molecular mechanistic insight into GardeninA-mediated neuroprotection against environmental toxin-induced Parkinson's disease pathogenesis for novel therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.